Together with other recent results of ours [16-18], the present observations suggest that clinical benefits in treating patients with breast cancer could be obtained with appropriate combinations of novel Akt inhibitors and conventional chemotherapeutic drugs or ionizing radiation. This evidence concerns the gene AKT1 and breast carcinoma.